Skip to content

Amphastar wins Momenta Lovenox patent fight in US jury trial

July 22, 2017

A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox.

The verdict by the jury in Boston came in a lawsuit by Cambridge, Massachusetts-based biotechnology company Momenta and its partner, Novartis AG’s Sandoz unit, that sought nearly $940 million in damages.

The jury found that while Rancho Cucamonga, California-based Amphastar had infringed Momenta’s patent, it was invalid and unenforceable.

“We’re extremely pleased with the jury verdict and that Amphastar is finally out from under this baseless lawsuit,” said Michael Sommer, a lawyer for Amphastar.

Momenta Chief Executive Craig Wheeler in a statement said the company was disappointed and was considering its options, including a potential appeal.

“We continue to believe in the importance of investing in innovative techniques for bringing products to market and protecting those innovations from unauthorized use,” he said.

Following the verdict, Amphastar’s stock price rose 2.29 percent to $18.33 while Momenta’s fell 2.32 percent to $16.85 on the NASDAQ stock exchange.

Sandoz did not respond to requests for comment.

Momenta and Sandoz filed the lawsuit in 2011 after the U.S. Food and Drug Administration approved Amphastar’s generic version of Sanofi SA’s blockbuster Lovenox, an anticoagulant used to treat and prevent blood clots.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: